{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:06:33Z","timestamp":1785391593776,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00210-025-04347-w","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T06:29:39Z","timestamp":1749623379000},"page":"17435-17444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A randomized trial on efficacy of purified cannabidiol on spasticity in multiple sclerosis patients with gait problems: first report in Iran"],"prefix":"10.1007","volume":"398","author":[{"given":"Pegah","family":"Mousavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1526-3765","authenticated-orcid":false,"given":"Maryam","family":"Emadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7769-7840","authenticated-orcid":false,"given":"Bahar","family":"Karimikhoshnoudian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3224-8807","authenticated-orcid":false,"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-0690","authenticated-orcid":false,"given":"Mehran","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6960-1265","authenticated-orcid":false,"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6599-833X","authenticated-orcid":false,"given":"Maryam","family":"Payere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Baghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0424-7460","authenticated-orcid":false,"given":"Aram","family":"Zabeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8373-6053","authenticated-orcid":false,"given":"Mohammadali","family":"Nahayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"4347_CR1","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1684\/epd.2019.1125","volume":"22","author":"C Anciones","year":"2020","unstructured":"Anciones C, Gil-Nagel A (2020) Adverse effects of cannabinoids. Epileptic Disord 22:S29\u2013S32","journal-title":"Epileptic Disord"},{"key":"4347_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/JMDH.S236275","volume":"13","author":"M Azadvari","year":"2020","unstructured":"Azadvari M, Naser Moghadasi A, Azimi AR, Sharifiaghdas F, Emami Razavi SZ, Eskandarieh S, Hosseini M, Rahimi-Dehgolan S, Sahraian MA (2020) Persian adaptation of actionable bladder symptom screening tool among patients with multiple sclerosis. J Multidiscip Healthc 13:79\u201383","journal-title":"J Multidiscip Healthc"},{"key":"4347_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R (1996) EuroQol: the current state of play. Health Policy 37:53\u201372","journal-title":"Health Policy"},{"key":"4347_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10072-009-0136-5","volume":"30","author":"D Centonze","year":"2009","unstructured":"Centonze D, Mori F, Koch G, Buttari F, Codec\u00e0 C, Rossi S, Cencioni MT, Bari M, Fiore S, Bernardi G, Battistini L, Maccarrone M (2009) Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci 30:531\u2013534","journal-title":"Neurol Sci"},{"key":"4347_CR5","doi-asserted-by":"crossref","unstructured":"Chayasirisobhon S (2021) The role of cannabidiol in neurological disorders. Perm J 255. Chayasirisobhon S (2021) The role of cannabidiol in neurological disorders. Perm J 25","DOI":"10.7812\/TPP\/20.156"},{"key":"4347_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1179\/016164109X12590518685660","volume":"32","author":"C Collin","year":"2010","unstructured":"Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, Notcutt W, O\u2019Leary C, Ratcliffe S, Nov\u00e1kov\u00e1 I, Zapletalova O, Pikov\u00e1 J, Ambler Z (2010) A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 32:451\u2013459","journal-title":"Neurol Res"},{"key":"4347_CR7","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502\u20131517","journal-title":"Lancet"},{"key":"4347_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1503\/cmaj.110837","volume":"184","author":"J Corey-Bloom","year":"2012","unstructured":"Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B (2012) Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ 184:1143\u20131150","journal-title":"CMAJ"},{"key":"4347_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15:545\u2013558","journal-title":"Nat Rev Immunol"},{"key":"4347_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11325-010-0478-5","volume":"16","author":"J Farrahi Moghaddam","year":"2012","unstructured":"Farrahi Moghaddam J, Nakhaee N, Sheibani V, Garrusi B, Amirkafi A (2012) Reliability and validity of the Persian version of the Pittsburgh Sleep Quality Index (PSQI-P). Sleep Breath 16:79\u201382","journal-title":"Sleep Breath"},{"key":"4347_CR12","doi-asserted-by":"crossref","unstructured":"Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K (2022) Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Database Syst Rev 5: Cd01344412. Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K (2022) Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Database Syst Rev 5: Cd013444","DOI":"10.1002\/14651858.CD013444.pub2"},{"key":"4347_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ana.24497","volume":"78","author":"JM Frischer","year":"2015","unstructured":"Frischer JM, Weigand SD, Guo Y, Kale N, Parisi JE, Pirko I, Mandrekar J, Bramow S, Metz I, Br\u00fcck W, Lassmann H, Lucchinetti CF (2015) Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 78:710\u2013721","journal-title":"Ann Neurol"},{"key":"4347_CR14","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3109\/09638288.2012.742575","volume":"35","author":"M Ghajarzadeh","year":"2013","unstructured":"Ghajarzadeh M, Jalilian R, Eskandari G, Ali Sahraian M, Reza Azimi A (2013) Validity and reliability of Persian version of Modified Fatigue Impact Scale (MFIS) questionnaire in Iranian patients with multiple sclerosis. Disabil Rehabil 35:1509\u20131512","journal-title":"Disabil Rehabil"},{"key":"4347_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/da.20070","volume":"21","author":"H Ghassemzadeh","year":"2005","unstructured":"Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N (2005) Psychometric properties of a Persian-language version of the Beck Depression Inventory-Second edition: BDI-II-PERSIAN. Depress Anxiety 21:185\u2013192","journal-title":"Depress Anxiety"},{"key":"4347_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/B978-0-444-52001-2.00010-8","volume":"122","author":"DS Goodin","year":"2014","unstructured":"Goodin DS (2014) The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol 122:231\u2013266","journal-title":"Handb Clin Neurol"},{"key":"4347_CR17","doi-asserted-by":"crossref","unstructured":"Hui D, Arg\u00e1ez C (2021) CADTH health technology review. Onabotulinum Toxin A (Botox) for Spasticity Associated With Multiple Sclerosis. Canadian Agency for Drugs and Technologies in Health17. Hui D, Arg\u00e1ez C (2021) CADTH health technology review. Onabotulinum Toxin A (Botox) for Spasticity Associated With Multiple Sclerosis. Canadian Agency for Drugs and Technologies in Health","DOI":"10.51731\/cjht.2021.43"},{"key":"4347_CR18","first-page":"557","volume":"97","author":"SA Isezuo","year":"2005","unstructured":"Isezuo SA, Ezunu E (2005) Demographic and clinical correlates of metabolic syndrome in Native African type-2 diabetic patients. J Natl Med Assoc 97:557\u2013563","journal-title":"J Natl Med Assoc"},{"key":"4347_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/13524585211017013","volume":"28","author":"A Kalinowski","year":"2022","unstructured":"Kalinowski A, Cutter G, Bozinov N, Hinman JA, Hittle M, Motl R, Odden M, Nelson LM (2022) The timed 25-foot walk in a large cohort of multiple sclerosis patients. Mult Scler 28:289\u2013299","journal-title":"Mult Scler"},{"key":"4347_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2174\/1574884711666160418105339","volume":"11","author":"R Kaur","year":"2016","unstructured":"Kaur R, Ambwani SR, Singh S (2016) Endocannabinoid system: a multi-facet therapeutic target. Curr Clin Pharmacol 11:110\u2013117","journal-title":"Curr Clin Pharmacol"},{"key":"4347_CR21","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1177\/1352458510378020","volume":"16","author":"RB Kavia","year":"2010","unstructured":"Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ (2010) Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 16:1349\u20131359","journal-title":"Mult Scler"},{"key":"4347_CR22","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s00415-012-6739-4","volume":"260","author":"RM Langford","year":"2013","unstructured":"Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S (2013) A double-blind, randomized, placebo-controlled, parallel-group study of THC\/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 260:984\u2013997","journal-title":"J Neurol"},{"key":"4347_CR23","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1007\/s00415-015-7878-1","volume":"262","author":"L Leocani","year":"2015","unstructured":"Leocani L, Nuara A, Houdayer E, Schiavetti I, Del Carro U, Amadio S, Straffi L, Rossi P, Martinelli V, Vila C, Sormani MP, Comi G (2015) Sativex(\u00ae) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. J Neurol 262:2520\u20132527","journal-title":"J Neurol"},{"key":"4347_CR24","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa1100648","volume":"365","author":"CF Lucchinetti","year":"2011","unstructured":"Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Br\u00fcck W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM (2011) Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365:2188\u20132197","journal-title":"N Engl J Med"},{"key":"4347_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.47102\/annals-acadmedsg.V32N5p685","volume":"32","author":"N Luo","year":"2003","unstructured":"Luo N, Chew LH, Fong KY, Koh DR, Ng SC, Yoon KH, Vasoo S, Li SC, Thumboo J (2003) Validity and reliability of the EQ-5D self-report questionnaire in Chinese-speaking patients with rheumatic diseases in Singapore. Ann Acad Med Singap 32:685\u2013690","journal-title":"Ann Acad Med Singap"},{"key":"4347_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.892165","volume":"13","author":"L Marinelli","year":"2022","unstructured":"Marinelli L, Puce L, Mori L, Leandri M, Rosa GM, Curr\u00e0 A, Fattapposta F, Trompetto C (2022) Cannabinoid effect and safety in spasticity following stroke: a double-blind randomized placebo-controlled study. Front Neurol 13","journal-title":"Front Neurol"},{"key":"4347_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/00207454.2018.1481066","volume":"129","author":"J Markov\u00e0","year":"2019","unstructured":"Markov\u00e0 J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C (2019) Sativex(\u00ae) as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int J Neurosci 129:119\u2013128","journal-title":"Int J Neurosci"},{"key":"4347_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bcp.2018.08.037","volume":"157","author":"L Mestre","year":"2018","unstructured":"Mestre L, Carrillo-Salinas FJ, Mecha M, Feli\u00fa A, Guaza C (2018) Gut microbiota, cannabinoid system and neuroimmune interactions: new perspectives in multiple sclerosis. Biochem Pharmacol 157:51\u201366","journal-title":"Biochem Pharmacol"},{"key":"4347_CR29","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.gaitpost.2014.11.003","volume":"41","author":"N Nakhostin Ansari","year":"2015","unstructured":"Nakhostin Ansari N, Naghdi S, Mohammadi R, Hasson S (2015) Multiple Sclerosis Walking Scale-12, translation, adaptation and validation for the Persian language population. Gait Posture 41:420\u2013424","journal-title":"Gait Posture"},{"key":"4347_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/pri.1799","volume":"25","author":"AD Norbye","year":"2020","unstructured":"Norbye AD, Midgard R, Thrane G (2020) Spasticity, gait, and balance in patients with multiple sclerosis: a cross-sectional study. Physiother Res Int 25","journal-title":"Physiother Res Int"},{"key":"4347_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-pathol-011811-132443","volume":"7","author":"BF Popescu","year":"2012","unstructured":"Popescu BF, Lucchinetti CF (2012) Pathology of demyelinating diseases. Annu Rev Pathol 7:185\u2013217","journal-title":"Annu Rev Pathol"},{"key":"4347_CR32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1191\/1352458504ms1085oa","volume":"10","author":"MA Rizzo","year":"2004","unstructured":"Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL (2004) Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 10:589\u2013595","journal-title":"Mult Scler"},{"key":"4347_CR33","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1212\/01.wnl.0000176753.45410.8b","volume":"65","author":"DJ Rog","year":"2005","unstructured":"Rog DJ, Nurmikko TJ, Friede T, Young CA (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65:812\u2013819","journal-title":"Neurology"},{"key":"4347_CR34","first-page":"10000122","volume":"1","author":"M Vachov\u00e1","year":"2014","unstructured":"Vachov\u00e1 M, Novotn\u00e1 A, Mares J, Tal\u00e1b R, Fiedler J, Lauder H, Taylor L, Etges T, Wright S, Nov\u00e1kov\u00e1 I (2014) A multicentre, double-blind, randomised, parallel-group, placebo-controlled study of effect of long-term Sativex\u00ae treatment on cognition and mood of patients with spasticity due to multiple sclerosis. J Mult Scler 1:10000122","journal-title":"J Mult Scler"},{"key":"4347_CR35","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.clinthera.2017.01.016","volume":"40","author":"G van Amerongen","year":"2018","unstructured":"van Amerongen G, Kanhai K, Baakman AC, Heuberger J, Klaassen E, Beumer TL, Strijers RLM, Killestein J, van Gerven J, Cohen A, Groeneveld GJ (2018) Effects on spasticity and neuropathic pain of an oral formulation of \u03949-tetrahydrocannabinol in patients with progressive multiple sclerosis. Clin Ther 40:1467\u20131482","journal-title":"Clin Ther"},{"key":"4347_CR36","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1001\/archneur.61.10.1613","volume":"61","author":"HL Weiner","year":"2004","unstructured":"Weiner HL (2004) Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 61:1613\u20131615","journal-title":"Arch Neurol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04347-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04347-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04347-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T04:29:41Z","timestamp":1764822581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04347-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4347"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04347-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the ethics committee of Mashhad University of Medical Sciences (IR.MUMS.MEDICAL.REC.1401.194), and the trial was registered with the Iranian Registry of Clinical Trials (IRCT) under the number IRCT20220815055709 N1- June 14, 2022.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}